Table 5 Multivariate analysis by prognostic factors for recurrence-free survival
From: Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer
Prognostic factors | Overall Cohort | EGFRm Cohort | PD-L1 Positive Cohort | |||
|---|---|---|---|---|---|---|
HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
CEA | ||||||
  < 3.8 ng/ml | Ref |  | Ref |  | - | - |
  ≥ 3.8 ng/ml | 6.31 (1.73–22.9) | 0.005 | 9.62 (2.80–33.02) |  < 0.001 | - | - |
pT | ||||||
 pT1 | Ref |  | - | - | - | - |
 pT2a | - | - | - | - | - | - |
 pT2b | 0.26 (0.02–3.14) | 0.294 | - | - | - | - |
 pT3 | 0.47 (0.07–3.05) | 0.437 | - | - | - | - |
 pT4 | 253.87 (2.59–24867.46) | 0.018 | - | - | - | - |
pN | ||||||
 pN0 | Ref | - | Ref | - | - | - |
 pN1 | 0.78 (0.06–8.97) | 0.848 | 5.36 (1.54–18.69) | 0.008 | - | - |
 pN2 | 49.5 (1.02–2393.91) | 0.049 | 2.77 (0.72–10.58) | 0.135 | - | - |
pStage | ||||||
 I | Ref |  | - | - | Ref |  |
 II | 44.01 (2.46–786.99) | 0.01 | - | - | 7.06 (1.35–36.87) | 0.02 |
 III | 0.710 (0.01–46.55) | 0.875 | - | - | 16.23 (3.61–72.87) |  < 0.001 |
Margin | ||||||
 Negative | Ref |  | Ref |  | - | - |
 Positive | 65.05 (4.06–1039.87) | 0.003 | 11.74 (1.99–69.18) | 0.006 | - | - |